Beractant - Biologic Drug Details

✉ Email this page to a colleague

Summary for beractant

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for beractant

Recent Clinical Trials for beractant

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Hospital Central "Dr. Ignacio Morones Prieto"	Phase 4
Universidad Autonoma de San Luis Potosí	Phase 4
King Edward Memorial Hospital, Pune	Phase 2/Phase 3

See all beractant clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for beractant Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for beractant Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for beractant Derived from Patent Text Search

No patents found based on company disclosures

Last updated: February 13, 2026

mmary
Beractant, a surfactant used to treat neonatal respiratory distress syndrome (NRDS), operates within the neonatal respiratory therapy segment. The market for surfactants like beractant faces growth driven by increasing preterm births globally, with technological advancements and regulatory approvals shaping its financial trajectory. The industry is characterized by moderate competition from other surfactants, a high entry barrier, and a pathway to premium pricing for innovative formulations.

What is the current market size and growth outlook for beractant?
The global neonatal respiratory distress syndrome (NRDS) therapeutics market, which includes surfactants like beractant, was valued at approximately $450 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of around 4.5% from 2023 to 2030. The growth is driven by increasing preterm births, which account for around 10% of all live births worldwide, and the rising adoption of advanced respiratory therapies in neonatal intensive care units (NICUs) (Source: Grand View Research).

Beractant, specifically, holds a significant share within the surfactant segment, estimated at roughly 40%, due to its established efficacy and safety profile.

What are the key market drivers and barriers?
Drivers:

Rising preterm birth rates increase demand for surfactant therapy to reduce mortality in neonates.
Advances in neonatal care with improved delivery methods and formulations.
Regulatory approvals expanding indications and labeling, boosting confidence for clinicians and hospitals.

Barriers:

High manufacturing costs and complex extraction processes limit profit margins.
Patent expirations of leading formulations lead to generic competition.
Supply chain issues, such as sourcing of surfactant components and cold chain logistics, affect availability.

How is the competitive landscape shaped?
The market features a few dominant players:

Chiesi Farmaceutici (market leader in surfactants)
GlaxoSmithKline (GSK), with its market-approved surfactants
Fuji Pharma and others
New entrants face extensive regulatory hurdles due to the critical nature of neonatal products and the requirement for rigorous safety and efficacy data.

Product differentiation relies on formulation stability, ease of administration, and reduced adverse effects. Patent filings increasingly focus on novel delivery platforms and improved bioavailability.

What is the financial trajectory for beractant?
Beractant’s revenue peaked when marketed as "Survanta," with sales reaching over $200 million annually at its height. Patent protections and manufacturing exclusivity continue to sustain its market valuation. However, with patent expirations over the last five years, sales have plateaued or declined in some regions, replaced by generics.

Pricing varies globally, with North American prices averaging $150–$200 per dose. Volume growth depends on neonatal ICU admissions and clinicians' preferences, which are shifting toward newer formulations and bioengineered surfactants.

Emerging markets have shown considerable growth potential, complying with increasing neonatal care investments. The global market for neonatal surfactants is expected to grow at a CAGR of 3-5% through 2030, influenced by demographic and healthcare expenditure trends.

What are the regulatory trends impacting beractant?
Increasing approvals for biosimilar surfactants and other biologics aim to introduce competition, reducing prices. The FDA’s 2021 guidance streamlines process requirements for biologics, encouraging innovation and market entry. Countries such as China, India, and Brazil are easing registration barriers to improve neonatal care access, potentially affecting the regional sales landscape.

The push for formulations with improved stability, reduced adverse effects, and simplified administration routes aligns with regulatory incentives to enhance neonatal safety and outcomes.

What future innovations could influence beractant’s market?
Developments include:

Liposomal or nanoparticle delivery systems to improve distribution and reduce doses.
Recombinant surfactant production methods to bypass extraction complexity.
Combination products integrating surfactants with adjunct therapies to improve efficacy.

Regulatory pathways for biosimilar and recombinant alternatives are improving, which may challenge traditional animal-extracted formulations like beractant.

Key Takeaways

The neonatal surfactant market, including beractant, will grow modestly, driven by birth rate trends and neonatal care investments.
Market competition is intensifying due to patent expirations and biosimilar developments.
Financially, beractant’s revenues are declining in mature markets but expanding in emerging regions.
Regulatory policies favor biosimilar entries, influencing pricing and market share.
Innovation focuses on delivery improvements and recombinant technologies, shaping future product pipelines.

FAQs

1. How does preterm birth impact beractant sales?
Preterm births increase demand for neonatal respiratory therapies like beractant, directly boosting sales. The global preterm birth rate influences regional market size.

2. What are the primary competitors to beractant?
Main competitors include other biologic surfactants such as Curosurf (poractant alfa) and Survanta (beractant's marketed form), plus generic versions following patent expiry.

3. How do regulatory changes affect beractant’s market?
Regulatory pathways for biosimilars and recombinant surfactants can lower barriers for new products, increasing competition and potentially decreasing prices of traditional beractant formulations.

4. What role will emerging markets play in beractant’s future?
Growth potential in regions like Asia-Pacific and Latin America is high due to rising healthcare expenditure and neonatal care investments.

5. How might innovations influence beractant’s viability?
Innovations such as liposomal delivery systems and recombinant manufacturing could reduce costs, improve efficacy, and extend market relevance, but may also introduce competitors.

Sources
[1] Grand View Research, "Neonatal Respiratory Distress Syndrome Therapeutics Market Size & Trends," 2022.

More… ↓

⤷ Start Trial